Arkolith/Insider Trading/APRE/Form 4

Henneman John B III

DirectorAprea Therapeutics, Inc. (APRE) · full profile →Form 4 · filed Mar 14, 2024
Net Buying
Open-Market Buys
$50K
Open-Market Sells
$0
Net Open-Market Flow
$50K
Transactions
3
1 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 13, 2024Buy(P)7K$7.29$50K8K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 13, 2024Buy(P)3K——3K
Mar 13, 2024Buy(P)3K——3K

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001104659-24-034671) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML